Abstract:Introduction Both mycophenolate mofetil (MMF) and intravenous cyclophosphamide (CYC) have been recommended in the induction therapy of lupus nephritis (LN) for years; nevertheless, their effectiveness and safety in a real-world setting are extremely lacking. Therefore, we decided to conduct this real-world study. Methods A total of 195 Chinese patients with LN who were initially treated with MMF ( n = 98), or intravenous CYC ( n = 97) as induction therapy were enrolled. All of the patients were followed up to 12 months. Complete renal remission (CRR) was defined as 24-h urinary protein (24 h-UTP) < 0.5 g, and partial renal remission (PRR) was defined as ≥ 50% reduction in 24 h-UTP to the subnephrotic level, however > 0.5 g, both with a change of serum creatinine (SCr) within 10% from baseline. The proportions of CRR, PRR, and total renal remission (TRR), as well as adverse events, were compared by Chi-square test and Kaplan–Meier analysis (log-rank test). Inverse probability of treatment weighting (IPTW) was used for propensity score matching and multivariable logistic regression analyses were employed. Results The cumulative proportion of TRR in 6 months (79.4 vs. 63.8%, p = 0.026) and CRR in 12 months (72.8 vs. 57.6%, p = 0.049) in MMF group were significantly higher than CYC group, and the above conclusions were further confirmed by IPTW. The proportions of PRR, CRR, and TRR at other time points were equivalent between two groups. Further subgroup analysis in 111 patients with biopsy-proven III–V LN also showed a significantly higher proportion of TRR at 6 months in the MMF group than in the CYC group (78.3 vs. 56.9%, p = 0.026). In the Kaplan–Meier analysis and after IPTW, the MMF group showed better TRR and CRR responses than CYC group in 12 months. Multivariable logistic regression analyses revealed that MMF use was the only predictor of CRR (HR 2.12, 95% CI 1.90–4.09, p = 0.026), while low complement level was also a predictor, albeit risk was reduced (HR 0.38, 95% CI 0.17–0.86, p = 0.019). Moreover, compared to the CYC group, MMF group patients were more likely to have significantly lower SCr (μmol/l) [72.5 (62.5, 86.5) vs. 79.0 (71.1, 97.5), p = 0.001] and daily dose of prednisone (mg/day) (15.7 ± 5.2 vs. 18.6 ± 11.3, p = 0.022) at 6 months; lower 24 h-UTP (g) [0.1 (0.1, 0.3) vs. 0.2 (0.1, 0.9), p = 0.005] and daily dose of prednisone (mg/day) (9.6 ± 3.3 vs. 11.2 ± 5.5, p = 0.023) at 12 months. Infection was the most common adverse event. Pneumonia and gastrointestinal discomfort were more frequently observed in the CYC group. Conclusions Real-world data are a key component of the evidence supporting the effectiveness of drugs and are of interest to all stakeholders. Our comparative study demonstrated the effectiveness of MMF in LN induction therapy was at least equivalent to intravenous CYC, with superior tolerance.

Cyclophosphamide Versus Mycophenolate Versus Rituximab in Lupus Nephritis Remission Induction: A Historical Head-to-Head Comparative Study

Multitarget Therapy for Induction Treatment of Lupus Nephritis A Randomized Trial

Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study.

Mycophenolate mofetil vs. cyclophosphamide-based induction regimens for lupus nephritis: Outcomes at a tertiary care centre in Lahore, Pakistan

Comparison of the Effectiveness and Safety of Mycophenolate Mofetil and Cyclophosphamide in Lupus Nephritis: Evidence from a Real-World Study

Efficacy and Safety of Cyclophosphamide Combined with Mycophenolate Mofetil for Induction Treatment of Class IV Lupus Nephritis.

Mizoribine Versus Mycophenolate Mofetil or Intravenous Cyclophosphamide for Induction Treatment of Active Lupus Nephritis.

Rituximab Treatment for Lupus Nephritis: A Systematic Review

Rituximab in systemic lupus erythematosus and lupus nephritis

Efficacy of low-dose leflunomide in lupus nephritis: A multi-center prospective study

Induction Therapies for Class IV Lupus Nephritis with Non-Inflammatory Necrotizing Vasculopathy: Mycophenolate Mofetil or Intravenous Cyclophosphamide.

Comparison of Different Usage of Cyclophosphamide in Lupus Nephritis: A Meta-analysis of Randomized Controlled Trails

Efficacy of individualized rituximab as the rescue therapy for active lupus nephritis with acute kidney injury

Rituximab or Cyclophosphamide in the Treatment of Membranous Nephropathy: The RI-CYCLO Randomized Trial.

Mycophenolate Mofetil or Tacrolimus Compared with Intravenous Cyclophosphamide in the Induction Treatment for Active Lupus Nephritis

Efficacy and safety of immunosuppressive agents for adults with lupus nephritis: a systematic review and network meta-analysis

Comparison of Different Uses of Cyreinishosphattlide in Lupus Nephritis: A IVIeta-Analysis of Randomized Controlled Trials

Short-term Outcomes of Induction Therapy with Tacrolimus Versus Cyclophosphamide for Active Lupus Nephritis: A Multicenter Randomized Clinical Trial

Short-interval lower-dose intravenous cyclophosphamide as induction and maintenance therapy for lupus nephritis: a prospective observational study

Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis

Comparison of efficacy of continuous mycophenolate mofetil with sequential cyclophosphamide and tacrolimus as maintenance therapy for lupus nephritis